Common Stocks - 98.5%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 20.0%
|
|||
Biotechnology - 20.0%
|
|||
2seventy bio, Inc. (a)(b)
|
183,600
|
2,877,012
|
|
ADC Therapeutics SA (a)(b)
|
419,700
|
1,536,102
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
34,671
|
7,648,076
|
|
Arcus Biosciences, Inc. (a)
|
115,100
|
4,048,067
|
|
Argenx SE (a)
|
15,200
|
6,151,963
|
|
Argenx SE ADR (a)
|
11,000
|
4,377,670
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
40,500
|
4,983,930
|
|
Avidity Biosciences, Inc. (a)
|
233,300
|
2,715,612
|
|
Biogen, Inc. (a)
|
65,300
|
19,927,601
|
|
BioInvent International AB (a)
|
1,318,105
|
4,526,263
|
|
Blueprint Medicines Corp. (a)
|
128,100
|
6,121,899
|
|
Cullinan Oncology, Inc. (a)
|
88,100
|
1,095,083
|
|
Cytokinetics, Inc. (a)
|
67,100
|
2,851,750
|
|
Galapagos NV sponsored ADR (a)
|
36,900
|
1,467,513
|
|
Generation Bio Co. (a)(b)
|
347,558
|
1,852,484
|
|
Gilead Sciences, Inc.
|
386,100
|
33,911,163
|
|
Intellia Therapeutics, Inc. (a)
|
15,400
|
792,484
|
|
iTeos Therapeutics, Inc. (a)
|
116,000
|
2,337,400
|
|
Kalvista Pharmaceuticals, Inc. (a)
|
374,800
|
2,020,172
|
|
Leap Therapeutics, Inc. warrants 1/31/26 (a)
|
606,000
|
30,452
|
|
Legend Biotech Corp. ADR (a)
|
293,400
|
15,113,034
|
|
Moderna, Inc. (a)
|
15,100
|
2,656,241
|
|
Oxurion NV (a)(b)
|
3,128,819
|
51,212
|
|
PepGen, Inc.
|
243,600
|
3,644,256
|
|
PTC Therapeutics, Inc. (a)
|
132,000
|
5,476,680
|
|
Relay Therapeutics, Inc. (a)(b)
|
168,000
|
3,121,440
|
|
Sarepta Therapeutics, Inc. (a)
|
107,700
|
13,226,637
|
|
SpringWorks Therapeutics, Inc. (a)(b)
|
44,300
|
1,071,174
|
|
Synlogic, Inc. (a)
|
520,500
|
311,363
|
|
uniQure B.V. (a)
|
150,300
|
3,976,938
|
|
Xencor, Inc. (a)
|
123,168
|
3,660,553
|
|
XOMA Corp. (a)(b)
|
53,300
|
1,128,361
|
|
164,710,585
|
|||
Food & Staples Retailing - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (a)
|
3,333
|
1,397
|
|
Health Care Providers & Services - 3.1%
|
|||
Health Care Services - 3.1%
|
|||
Cigna Corp.
|
51,900
|
17,069,391
|
|
Guardant Health, Inc. (a)
|
156,500
|
8,191,210
|
|
25,260,601
|
|||
Pharmaceuticals - 75.4%
|
|||
Pharmaceuticals - 75.4%
|
|||
Arvinas Holding Co. LLC (a)
|
55,600
|
2,281,824
|
|
AstraZeneca PLC sponsored ADR
|
1,484,900
|
100,928,653
|
|
Axsome Therapeutics, Inc. (a)(b)
|
43,400
|
3,137,386
|
|
Bristol-Myers Squibb Co.
|
755,880
|
60,682,046
|
|
Edgewise Therapeutics, Inc. (a)(b)
|
541,684
|
4,848,072
|
|
Eli Lilly & Co.
|
321,661
|
119,361,963
|
|
Euroapi SASU (a)
|
163,500
|
2,918,685
|
|
GSK PLC sponsored ADR
|
515,160
|
17,819,384
|
|
Harmony Biosciences Holdings, Inc. (a)(b)
|
73,077
|
4,367,812
|
|
Intra-Cellular Therapies, Inc. (a)
|
91,200
|
4,944,864
|
|
Jazz Pharmaceuticals PLC (a)
|
31,600
|
4,958,356
|
|
Johnson & Johnson
|
125,350
|
22,312,300
|
|
Merck & Co., Inc.
|
357,636
|
39,382,876
|
|
Merck KGaA
|
128,200
|
23,488,173
|
|
Novartis AG sponsored ADR
|
216,396
|
19,380,426
|
|
Pharvaris BV (a)
|
64,039
|
131,920
|
|
Pliant Therapeutics, Inc. (a)
|
69,631
|
1,279,818
|
|
Roche Holding AG (participation certificate)
|
132,336
|
43,224,100
|
|
Royalty Pharma PLC
|
888,500
|
39,067,345
|
|
Sanofi SA sponsored ADR
|
1,720,022
|
78,002,998
|
|
UCB SA
|
261,800
|
21,131,591
|
|
Zoetis, Inc. Class A
|
41,700
|
6,427,638
|
|
Zogenix, Inc. rights (a)(c)
|
800
|
544
|
|
620,078,774
|
|||
TOTAL COMMON STOCKS
(Cost $563,709,314)
|
810,051,357
|
||
Convertible Preferred Stocks - 0.6%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 0.3%
|
|||
Biotechnology - 0.3%
|
|||
Castle Creek Biosciences, Inc.:
|
|||
Series D1 (c)(d)
|
6,308
|
1,285,192
|
|
Series D2 (c)(d)
|
85
|
17,318
|
|
ValenzaBio, Inc. Series A (a)(c)(d)
|
224,708
|
1,332,518
|
|
2,635,028
|
|||
Diversified Financial Services - 0.3%
|
|||
Other Diversified Financial Services - 0.3%
|
|||
Paragon Biosciences Emalex Capital, Inc.:
|
|||
Series C (a)(c)(d)
|
158,879
|
1,720,660
|
|
Series D1 (c)(d)
|
14,400
|
155,952
|
|
Series D2 (c)(d)
|
22,477
|
243,426
|
|
2,120,038
|
|||
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Castle Creek Pharmaceutical Holdings, Inc. Series C (a)(c)(d)
|
200
|
44,304
|
|
Software - 0.0%
|
|||
Systems Software - 0.0%
|
|||
Evozyne LLC Series A (a)(c)(d)
|
5,900
|
91,981
|
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $5,635,754)
|
4,891,351
|
||
Money Market Funds - 1.9%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 3.86% (e)
|
3,332,860
|
3,333,527
|
|
Fidelity Securities Lending Cash Central Fund 3.86% (e)(f)
|
12,536,329
|
12,537,583
|
|
TOTAL MONEY MARKET FUNDS
(Cost $15,871,110)
|
15,871,110
|
||
TOTAL INVESTMENT IN SECURITIES - 101.0%
(Cost $585,216,178)
|
830,813,818
|
NET OTHER ASSETS (LIABILITIES) - (1.0)%
|
(8,140,117)
|
NET ASSETS - 100.0%
|
822,673,701
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Level 3 security
|
(d)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $4,891,351 or 0.6% of net assets.
|
(e)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(f)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Castle Creek Biosciences, Inc. Series D1
|
4/19/22
|
1,356,409
|
Castle Creek Biosciences, Inc. Series D2
|
6/28/21
|
14,700
|
Castle Creek Pharmaceutical Holdings, Inc. Series C
|
12/09/19
|
82,370
|
Evozyne LLC Series A
|
4/09/21
|
132,573
|
Paragon Biosciences Emalex Capital, Inc. Series C
|
2/26/21
|
1,700,005
|
Paragon Biosciences Emalex Capital, Inc. Series D1
|
10/21/22
|
155,952
|
Paragon Biosciences Emalex Capital, Inc. Series D2
|
5/18/22
|
193,747
|
ValenzaBio, Inc. Series A
|
3/25/21
|
1,999,998
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 3.86%
|
10,726,575
|
241,015,774
|
248,408,822
|
93,426
|
-
|
-
|
3,333,527
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 3.86%
|
7,039,136
|
299,249,449
|
293,751,002
|
43,382
|
-
|
-
|
12,537,583
|
0.0%
|
Total
|
17,765,711
|
540,265,223
|
542,159,824
|
136,808
|
-
|
-
|
15,871,110
|
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Oxurion NV
|
-
|
4,984,659
|
-
|
-
|
-
|
(4,933,447)
|
-
|
Total
|
-
|
4,984,659
|
-
|
-
|
-
|
(4,933,447)
|
-
|